FDA Establishes Regulatory Review Period for Crenessity
February 13, 2026
February 13, 2026
WASHINGTON, Feb. 13 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced the determination of the regulatory review period for the human drug product Crenessity. This notice follows the submission of applications by Neurocrine Biosciences Inc., San Diego, California, to the U.S. Department of Commerce Patent and Trademark Office for the extension of several patents.
Crenessity, known as crinecerfont, is an adjunctive treatment used with . . .
Crenessity, known as crinecerfont, is an adjunctive treatment used with . . .